# Temperature Excursion Management > Site directory and reading guidance: [llms.txt](https://wiki.skusavvy.com/llms.txt). Canonical URL: https://wiki.skusavvy.com/article/temperature-excursion-management Published: 2026-11-06T00:08:09.817Z Last updated: 2026-11-06T01:32:18.403Z Category: Supply Chain > This article is AI-assisted reference material. Verify important or time-sensitive claims against the cited sources; AI review does not establish independent factual verification. ## Overview **Temperature excursion management** is the coordinated operational and quality-assurance process for detecting, containing, assessing, and resolving a departure from a product’s specified temperature limits during storage or transit. It is used for temperature-sensitive goods in the life sciences, healthcare, food distribution, and chemical sectors, including pharmaceuticals, vaccines, biologics, active pharmaceutical ingredients (APIs), and perishable foodstuffs. The primary objective is to keep potentially compromised materials from clinical or consumer use until a documented disposition is made, and to retain defensible records for that decision. An excursion is a measured departure from a specified limit, not automatic proof that a product is unsuitable. Evaluation depends on the product, the temperatures reached, the duration and pattern of exposure, the quality of the measurement, and available stability or safety data. Regulatory and industry guidance addresses parts of this process: the [CDC vaccine storage and handling guidance](https://www.cdc.gov/vaccines/hcp/imz-best-practices/storage-handling.html) describes emergency response and data-logger review for vaccines; [EU good distribution practice guidance](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52013XC1123(01)) requires medicinal-product deviations to be investigated and documented; and the [World Health Organization’s guidelines on good distribution practices for pharmaceutical products](https://www.who.int/publications/m/item/annex-5-guidelines-on-the-good-distribution-practices-for-pharmaceutical-products) call for quality risk management, temperature control where required, and investigation of deviations. ## Etymology and Origins *Excursion* derives from the Latin noun *excursio* (“a running out or forth”), from *excurrere* (*ex-*, “out,” and *currere*, “to run”). In technical English it came to mean a temporary movement beyond a normal or specified boundary. That [linguistic history](https://www.merriam-webster.com/dictionary/excursion) long predates its use in logistics and quality management. In cold-chain distribution, the phrase became established as quality systems moved from informal checks toward documented Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP). Pharmaceutical distribution rules now connect detected temperature events with [documented deviations, investigations, and corrective measures](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52013XC1123(01)). ## Historical Development Moving temperature-sensitive biological material predates instrumented monitoring. [Edward Jenner’s smallpox vaccination work began in 1796](https://www.who.int/news-room/spotlight/history-of-vaccination/history-of-smallpox-vaccination). Early vaccine material was biologically fragile, and later long-distance immunization campaigns had to manage that fragility; those later transport methods should not be attributed to Jenner’s initial experiments. Through the nineteenth and early twentieth centuries, perishable cargo commonly relied on ice, insulated containers, and mechanically refrigerated rail and ship equipment as those technologies spread. Strip-chart recorders later provided continuous analog temperature traces, but they did not generate real-time alarms and could be affected by mechanical failure or poor maintenance. Compact electronic data loggers became practical as microprocessors shrank and fell in cost during the late twentieth century. Separately, [USP <1079> Good Storage and Distribution Practices for Drug Products](https://www.uspnf.com/) now provides a pharmacopeial framework for storage and distribution controls, temperature mapping, monitoring, and excursion handling. Its current text should not be dated to the first appearance of electronic loggers. A clear regulatory milestone is the [2013 EU Guidelines on Good Distribution Practice of Medicinal Products for Human Use](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52013XC1123(01)). Those guidelines cover outsourced activities, require suitable temperature conditions and monitoring for medicinal products that need them, and require deviations to be recorded and investigated, with corrective and preventive action where appropriate. In the United States, [21 CFR 211.142](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-H/section-211.142) requires drug products to be stored under appropriate conditions, while [21 CFR 211.150](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-H/section-211.150) requires written distribution procedures. Current systems may combine Bluetooth Low Energy, cellular, or satellite sensors with warehouse controls so suspect goods can be held before they are put away or picked. ## Core Concepts ### Limits and Measurement Allowable limits come from the product registration, label, stability data, food-safety specifications, or a quality agreement. Common labeled examples include refrigerated storage at +2°C to +8°C and, in many European and WHO contexts, controlled room temperature at +15°C to +25°C. U.S. Pharmacopeial controlled room temperature is not identical: it is generally +20°C to +25°C, with defined brief excursions permitted. Frozen and cryogenic ranges, such as about −20°C, ultra-low freezer temperatures near −80°C, or liquid-nitrogen conditions approaching −196°C, are product-specific and must not be treated as interchangeable. An alarm threshold is often set inside the product limit so staff can intervene before a true excursion. Air temperature can change quickly when a door opens, while liquid or dense product changes more slowly. Assessment should therefore consider probe placement, calibration, sampling interval, time synchronization, and whether a buffered probe was used. [EU distribution guidance](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52013XC1123(01)) expects temperature mapping and monitoring appropriate to the product and equipment. [CDC guidance](https://www.cdc.gov/vaccines/hcp/imz-best-practices/storage-handling.html) calls for digital data loggers with buffered probes for vaccine storage so readings better reflect product temperature. ### Exposure, Stability, and Mean Kinetic Temperature Assessment looks at peak temperature, time outside limits, repeated cycling, and, where scientifically justified, cumulative thermal exposure. Chemical degradation rates often increase with temperature, a relationship described by the Arrhenius equation and used in [ICH stability guidance](https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf) to design stability studies. That kinetic model does not by itself authorize release after an excursion. Mean kinetic temperature (MKT) is a calculated single temperature intended to represent the cumulative chemical effect of a varying temperature history. Pharmacopeial discussion of MKT is limited. It is not a substitute for product-specific stability data, and it is not appropriate for justifying exposure of proteins, many biologics, or vaccines that can be damaged by freezing, agitation, or aggregation. A freeze event can make averaging irrelevant. ## Response and Disposition A typical written procedure has several stages. Exact steps depend on the product, contract, and jurisdiction: 1. **Protect and contain.** Restore suitable conditions if it is safe to do so, and physically quarantine affected goods. Place a system hold so they cannot be picked, packed, or transferred. Do not discard goods before the responsible quality authority has decided their disposition. 2. **Preserve evidence.** Retain raw logger files, calibration records, shipment documents, timestamps, packaging condition, and the status of refrigerants, dry ice, or phase-change materials. Preserve original data rather than only summary screenshots. 3. **Notify responsible parties.** Alert quality assurance, the product owner or marketing-authorization holder, and relevant logistics partners according to the quality agreement. Workflow tools can route those alerts; warehouse notification and workflow settings are one operational example, not a regulatory requirement. 4. **Assess impact.** Compare the reconstructed profile with approved stability, labeling, or food-safety data. Prior excursions and the remaining shelf life may matter. The product owner, not the carrier or warehouse alone, is generally responsible for scientific disposition of a regulated healthcare product. 5. **Document disposition.** An authorized person records release, restricted use, shortened dating if permitted, return, rework, or destruction. Inventory software can enforce the hold, but it does not replace the quality decision. 6. **Investigate and prevent recurrence.** Identify causes such as equipment failure, incorrect set points, delays, or inadequate packaging, and record corrective and preventive actions. For vaccines, [CDC storage and handling guidance](https://www.cdc.gov/vaccines/hcp/imz-best-practices/storage-handling.html) directs providers to quarantine affected vaccines and contact the manufacturer or immunization program before use or disposal. Lot-tracking functionality can identify which batches were in the affected location; segregation in an inventory system still requires a separate, documented quality disposition. ## Industry Applications and Examples The following cases are illustrative, not reports of specific incidents or evidence that a stated time and temperature is generally acceptable. **Pharmaceuticals and vaccines.** Suppose a refrigerated zone loses cooling over a weekend. Staff quarantine the location and, using lot and expiration-date records, identify every lot stored there. If loggers show a peak of +11.2°C for 3.5 hours, quality personnel can release the goods only when the marketing-authorization holder’s stability data or written excursion budget supports that specific product and history. A tolerance shown for one product cannot be copied to another. **Perishable food.** Suppose a refrigerated delivery arrives with a recorder showing +9.0°C for more than six hours, above the shipper’s specified +4.0°C limit. Those numbers are contractual or commodity specifications in this example; they are not universal limits in the [U.S. sanitary transportation rule](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-1/subpart-O). That rule requires sanitary transportation practices and records for covered food and, in specified circumstances, gives the carrier and shipper an opportunity to demonstrate that a temperature deviation did not render the food unsafe. Absent that demonstration, the receiver should not place the food into saleable stock. **Cell and gene therapies.** Some therapies are shipped in vapor-phase liquid-nitrogen shippers at cryogenic temperatures. Loss of vacuum insulation or excessive hold time can warm the payload. Serialized item-level product records can identify the affected unit, but release depends on the manufacturer’s chain-of-custody and temperature criteria, not on warehouse identification alone. ## Technology, Controls, and Best Practices Controls normally combine qualified packaging, calibrated monitoring, and inventory holds: - **Packaging qualification.** Insulated shippers and refrigerants should be qualified against the lanes and seasonal profiles in which they will be used. [ISTA test procedures](https://ista.org/), including thermal procedures in the 7-Series, are widely used industry methods; selecting 7D, 7E, or another procedure depends on parcel or freight mode and the study design. - **Mapping and placement.** Storage areas and vehicles should be mapped under representative loads and seasons to locate warm and cold spots, including positions near doors and airflow paths. - **Monitoring.** Independent loggers or telematics may record temperature and, where relevant, location, shock, or light. A receiving procedure can require the record to be reviewed before putaway. [Purchase-order receiving workflows](https://www.skusavvy.com/docs/guides/purchase-orders/receiving) can capture inspection results, but they do not themselves interpret temperature data. - **Performance measures.** Useful indicators can include excursion rate by lane or carrier, time to quarantine, completeness of monitoring records, and repeat deviations. “Mean time to excursion containment” is an internal metric if an organization defines it; it is not a recognized regulatory standard. ## Standards and Regulatory Considerations - **United States:** [21 CFR 211.142](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-H/section-211.142) addresses appropriate drug-product storage, and [21 CFR 211.150](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-H/section-211.150) requires written distribution procedures. The Food Safety Modernization Act sanitary-transportation requirements in [21 CFR Part 1, Subpart O](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-1/subpart-O) cover specified human and animal foods, not drugs generally. - **European Union:** The [2013 EU GDP Guidelines](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52013XC1123(01)) address equipment, temperature control and mapping where relevant, transport, outsourced activities, and deviation management for medicinal products. - **International and pharmacopeial guidance:** [WHO GDP guidance](https://www.who.int/publications/m/item/annex-5-guidelines-on-the-good-distribution-practices-for-pharmaceutical-products) and [USP <1079>](https://www.uspnf.com/) provide internationally used baselines. They guide risk assessment and monitoring; they do not replace product-specific approval conditions or national law. ## Source links - [CDC Vaccine Storage and Handling Guidance]() - [EU Guidelines on Good Distribution Practice of Medicinal Products for Human Use]() - [Merriam-Webster: Excursion]() - [WHO: History of Smallpox Vaccination]() - [21 CFR 211.150: Distribution Procedures]() - [21 CFR Part 1, Subpart O: Sanitary Transportation of Human and Animal Food]() - [WHO Guidelines on Good Distribution Practices for Pharmaceutical Products (Annex 5)]() - [United States Pharmacopeia (USP) \<1079\> Good Storage and Distribution Practices]() - [International Safe Transit Association (ISTA) Standards]() - [SkuSavvy Purchase Order Receiving Documentation]() - [21 CFR 211.142: Warehousing Procedures]() - [ICH Q1A(R2): Stability Testing of New Drug Substances and Products]()